Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. - Wikidata - wikimedia - TriplyDB

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

http://www.wikidata.org/entity/Q41646881

about

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer Liquid biopsy genotyping in lung cancer: ready for clinical utility?Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Molecular Testing of Lung Cancers Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients.Optimized expression-based microdissection of formalin-fixed lung cancer tissue.Harnessing plasma genotyping for precision therapy against lung cancer.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.Current and Emerging Applications of Droplet Digital PCR in Oncology.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.Osimertinib for the treatment of non-small cell lung cancer.Targeting the EGFR T790M mutation in non-small-cell lung cancer.Liquid Biopsy in Non-Small Cell Lung Cancer.Pharmacological management of relapsed/refractory NSCLC with chemical drugs.Targeting ALK: Precision Medicine Takes on Drug Resistance.Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Integrating liquid biopsies into the management of cancer.Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets.Sequencing brain metastases and opportunities for targeted therapies.Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer.Lung cancer as a paradigm for precision oncology in solid tumours.Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC.Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time use.Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?

P2860

Q28069708-75CF539A-4D76-4860-A163-5BB89C02F5CF Q28079253-CFA0DE3B-C0A9-449E-BAD9-EEC80325BCE5 Q33567037-181C35BD-A95B-48EF-A956-6BF1A2D173FF Q33621143-67D5F3BA-8CE2-4B1D-8109-F71F854672C8 Q33729715-CA17F9E2-CC91-4C28-8499-D1B2F69007F5 Q33740707-8482899F-C740-4055-BFA7-E569066B3DB7 Q33757134-0264F353-8A4E-4386-B964-5E610836F263 Q33825515-E33117BE-CA45-4340-8D05-81D1CDA10EAD Q36354945-23390659-5ACF-4C6F-A3A6-9FE8B01783EF Q37411128-42556685-9FD0-4C6B-9D9C-BF10801028A8 Q37637905-9D62DD75-7843-40EF-9CBC-5C63769F6104 Q37690677-0402DBF4-8389-46B0-8A5F-D258D0D530D9 Q37695228-5F5E449A-4089-41F4-9687-37FDAF979386 Q37698613-53D97B1E-9AFE-4440-A8F7-DFE51FC1426C Q38374623-B13EFE2A-BB1B-423A-941F-000A9A5287F9 Q38598893-5234ED87-6645-4EE8-93DA-38D016B9C734 Q38651333-B99B523D-4DFC-470B-979C-E867C5AB78B8 Q38694431-F20845C7-61B1-4C18-8E62-BAA528196F4F Q38824891-86A715F2-DA21-41AD-B118-BA048D0B74FD Q39002726-31A925E7-05AC-4D03-90C0-D1BE3C7A5EBB Q39047294-8C16B9D3-193E-402F-90F7-12CAAA7B89F8 Q39076207-DE7BC7EC-45AA-4075-9111-2DC9D4B270E2 Q39095285-D416EF70-F2AC-4ACE-81AC-603A704CC098 Q39103431-C77338C7-6D12-49DA-A42D-0934695F8F39 Q39106800-715BADB8-3F2D-411E-8B24-F3836313B195 Q39149201-109C793C-12BA-4B8D-AD9A-ED3F9C350779 Q39157824-C0CDB51A-1832-4B83-8654-AAF15018F58B Q39172297-BC503565-5CBE-496E-B5AC-6B16E4C96BE3 Q39177404-90463F51-B7E2-4DB0-9B81-EDF32EDD44F5 Q39197920-165BA3DD-3976-4988-84C1-2EEFC043EE0F Q39436392-1B1398E9-D72C-43A0-8FA8-B388BB81AB39 Q39449763-90C9229A-E313-466A-A1C9-918CB47D328F Q40489387-31FBF251-7AB5-4356-A904-7773C0A9BF75 Q40498036-04F9C653-32EE-4B8B-9DC7-C90E439361CD Q40502030-E2D127C2-5BB8-4FD2-BCCE-FC0840D5FC8A Q40996780-7C2D3C1C-5067-4D79-831B-E04AE8AE5455 Q41189462-CF13905D-237F-4092-B4B3-4E8C99D72CA4 Q41605055-64602919-598E-47A5-B655-C4619C8EC14B Q42283950-DA7E775D-7995-4603-8648-B70E2B3CFD20 Q42329924-2E29D582-6A4A-4884-81DA-7B489CFCA4C1

P2860

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

http://www.wikidata.org/entity/Q41646881

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Association Between Plasma Gen ...... ed Non-Small-Cell Lung Cancer.

@en

type

label

Association Between Plasma Gen ...... ed Non-Small-Cell Lung Cancer.

@en

prefLabel

Association Between Plasma Gen ...... ed Non-Small-Cell Lung Cancer.

@en

P1433

Q41646881-F6B36C04-8A06-4735-837D-320BF0273E19

P1476

Q41646881-BE1F3B6C-8041-463D-A8CA-6FE8F18EACE2

P2093

Q41646881-0A1399CA-B317-4B16-A937-1E140199B4C6

Q41646881-47BF5E66-680A-4F25-B33E-455DE2B9AEFE

Q41646881-503C311A-D1A2-46D6-A985-F739AA662116

Q41646881-59707B3C-039C-49DE-B604-57D9988C3C7E

Q41646881-59B56272-85C2-4021-AB18-98AC3F65A8FE

Q41646881-7C9B8E8F-9C50-4420-8C21-EBFEFE9730BF

Q41646881-BDDEE305-5C36-4E46-A74A-FA5FBB0EB1DD

Q41646881-E7D46869-57F9-4539-B80F-B34D030CBB8A

P2860

Q41646881-1F85AA58-80C8-422F-8004-BE2AAAAF1822

Q41646881-2BCB311A-D84A-44C5-B8FD-3257D0C7C276

Q41646881-2D6E8038-DF75-4246-A8E3-DDD8B79240AF

Q41646881-55F080AE-2F40-424F-B5D0-DB8922A5882F

Q41646881-5F4D6181-998A-4B40-9DD8-A20464F03FD7

Q41646881-6FD0565D-102F-4E66-80B4-6522AE9DC471

Q41646881-7B98EF6F-9C3B-402A-80F0-1A6539FAE878

Q41646881-821C400F-5FAD-46BA-9CC9-0A83B3C74938

Q41646881-897600E9-3C6E-4139-B7A8-5C79AA613DB9

Q41646881-91DE44A1-DDE4-456E-8CFA-29F2A2905B04

P304

Q41646881-E080E37E-D558-4A5E-9E0D-8CF3F122669E

P31

Q41646881-84CE69BD-FBBC-4416-8CAF-A4941AC850A4

P356

Q41646881-BAC3781B-FE02-4FDE-B5E8-5BC0F2E87873

P407

Q41646881-017A279F-EEDB-4CEE-9484-33D95B53AD52

P433

Q41646881-A45BB441-18F2-4004-9056-6D2215FCAF88

P478

Q41646881-1820EA93-1DE7-49F6-B458-6B8B2B05E15D

P50

Q41646881-4FB2022C-0B3E-4ED8-B3CD-DEB58726B867

P577

Q41646881-DA15DBA8-974C-4035-B081-B47D15431908

P698

Q41646881-8270AAB1-AE42-4A58-894B-1DD7FD14D7EF

P932

Q41646881-ABF660CC-C339-442B-83E1-CE793939E15D

P356

JCO.2016.66.7162

P1433

Journal of Clinical Oncology

P1476

Association Between Plasma Gen ...... ed Non-Small-Cell Lung Cancer.

@en

P2093

Cloud P Paweletz

http://www.w3.org/2001/XMLSchema#string

Geoffrey R Oxnard

http://www.w3.org/2001/XMLSchema#string

J Carl Barrett

http://www.w3.org/2001/XMLSchema#string

James Chih-Hsin Yang

http://www.w3.org/2001/XMLSchema#string

Kenneth S Thress

http://www.w3.org/2001/XMLSchema#string

Mireille Cantarini

http://www.w3.org/2001/XMLSchema#string

Rachael Lawrance

http://www.w3.org/2001/XMLSchema#string

Ryan S Alden

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status

P304

3375-3382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.66.7162

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27354477

http://www.w3.org/2001/XMLSchema#string

P932

5035123

http://www.w3.org/2001/XMLSchema#string